Why PBC Patients Underreport the Itch

Key Takeaways:

• Pruritus affects roughly two-thirds of patients with primary biliary cholangitis (PBC) and is described as embarrassing, sleep-disrupting, and damaging to self-image, yet it is frequently underreported.
• Because itch intensity does not correlate with alkaline phosphatase (ALP), bilirubin, or disease stage, clinicians cannot infer it from biochemistry, and patients often do not volunteer it.
• Routine, direct elicitation – including its effect on sleep and social life – surfaces a treatable, quality-of-life-defining symptom that lab work will not reveal.

For the clinician managing primary biliary cholangitis (PBC), a follow-up visit is often anchored by the biochemical response: alkaline phosphatase (ALP), bilirubin, and the trajectory of cholestasis. Those markers answer questions about disease control and prognosis. They do not, however, capture one of the symptoms patients describe as most disruptive to daily life.

Pruritus affects roughly two-thirds of patients with PBC over the disease course, and evidence consistently shows that its severity is decoupled from the laboratory picture. The result is a clinical blind spot: a common, treatable, and quality-of-life-defining symptom that frequently goes unspoken unless the clinician asks directly.

A severe symptom that rarely surfaces

The gap between how burdensome pruritus is and how rarely it comes up in the encounter is striking. In the 2026 In America survey of patients with PBC, 68 percent – roughly two-thirds – reported itching or rash.¹

What the open-ended responses add is the texture that a prevalence figure cannot. One respondent described skin issues as "the worst for me. Rashes, hives, open sores that come up overnight. Itching, painful, embarrassing. Very hard on my self-image, making me feel like staying away from groups or new people."¹

Embarrassment recurs as a theme, with another patient noting simply that "the itching can be embarrassing." A symptom framed by patients in terms of shame and social withdrawal is, almost by definition, one they are unlikely to raise without prompting.¹

Why the labs will not reveal it

The instinct to read symptom burden off the biochemistry does not hold for cholestatic pruritus. Itch can arise at any stage of PBC, independent of the severity of cholestasis, and in advanced or cirrhotic disease, it may paradoxically diminish or disappear even as cholestasis persists.²

Investigators have documented a lack of correlation between laboratory cholestasis markers and itch intensity. Quality-of-life data points in the same direction: In the validation cohort for the PBC-40, the disease-specific quality-of-life instrument that includes a dedicated itch domain, no PBC-40 domain score correlated significantly with self-reported disease stage, time since diagnosis, age, or sex.^2,3

For the clinician, the practical implication is direct – a reassuring ALP trend says nothing about whether a patient is being kept awake by itch, and the only reliable way to know is to ask.

The sleep and social dimensions

Pruritus in PBC characteristically follows a circadian rhythm, worsening in the evening and overnight. Patients describe this directly, reporting that the itching is especially bad "when going to bed."^1,2

That timing matters because the link between itch and sleep is not incidental. In a post-hoc analysis of the Phase 2b GLIMMER trial in patients with PBC and moderate-to-severe pruritus, changes in itch severity correlated strongly with changes in sleep interference – weekly itch and sleep scores correlated at r = 0.88, and monthly scores at r = 0.84. In other words, as the itch moved, sleep moved with it.⁴

Layered onto the embarrassment and social withdrawal patients describe, pruritus emerges not as a peripheral nuisance but as a symptom that erodes rest, mood, and social engagement at once.

Eliciting and quantifying itch routinely

Because pruritus will not announce itself in the chart or the conversation, the practical step is to build elicitation into the visit. Many patients do not connect the itch to their liver disease, which is one more reason it goes unmentioned.²

Asking about it at diagnosis and at every follow-up – rather than waiting for the patient to raise it – is the recommended approach. Useful framing moves beyond "any itching?" to the dimensions patients actually experience: whether itch is disturbing sleep, whether it is worse at night, and whether it is affecting social comfort or self-image.²

A simple numeric rating scale gives the symptom a trackable value across visits, the same instrument used to quantify itch severity in clinical research. Directly elicited and quantified, pruritus becomes visible as what it is – a common and treatable symptom that biochemical monitoring alone will never surface.^2,4